Delisting riskPopularity #3,931
Hyperfine (HYPR)
Makes and supports Swoop, a portable ultra-low-field brain-MRI system.
$0.8200
After hours+0.01 (+1.31%)
At close$0.8094(+3.62%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 5 | 4 | 4 |
| Cost of revenue | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 |
| Gross profit | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 |
| 13 | 13 | 12 | 13 | 13 | 12 | 12 | 11 | 11 | 10 | 11 | 10 | |
| Research & development | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 4 | 4 | 4 | 4 |
| 7 | 7 | 6 | 7 | 7 | 6 | 7 | 6 | 7 | 7 | 7 | 7 | |
| Selling & marketing | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 |
| General & administrative | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Operating income | −12 | −12 | −11 | −11 | −11 | −11 | −11 | −10 | −9 | −8 | −9 | −8 |
| 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | −2 | 2 | 0 | −1 | |
| Interest income | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other non-operating income | 0 | −1 | −1 | −1 | −1 | 0 | −1 | 0 | 2 | −2 | 0 | 0 |
| Income before tax | −11 | −11 | −10 | −10 | −10 | −10 | −9 | −9 | −11 | −6 | −9 | −9 |
| Net income from continuing operations | −11 | −11 | −10 | −10 | −10 | −10 | −9 | −9 | −11 | −6 | −9 | −9 |
| Net income | −11 | −11 | −10 | −10 | −10 | −10 | −9 | −9 | −11 | −6 | −9 | −9 |
| EPS, basic | −$0.15 | −$0.15 | −$0.14 | −$0.14 | −$0.14 | −$0.14 | −$0.12 | −$0.12 | −$0.14 | −$0.06 | −$0.09 | −$0.09 |
| EPS, diluted | −$0.15 | −$0.15 | −$0.14 | −$0.14 | −$0.14 | −$0.14 | −$0.12 | −$0.12 | −$0.14 | −$0.06 | −$0.09 | −$0.09 |
| Weighted average shares, basic | 71 | 72 | 72 | 72 | 73 | 73 | 76 | 78 | 79 | 94 | 98 | 100 |
| Weighted average shares, diluted | 71 | 72 | 72 | 72 | 73 | 73 | 76 | 78 | 79 | 94 | 98 | 100 |
| EBITDA | −11 | −10 | −10 | −10 | −10 | −10 | −9 | −9 | −11 | −5 | −8 | −8 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| EBIT | −12 | −11 | −10 | −10 | −10 | −10 | −9 | −9 | −11 | −6 | −9 | −9 |
